Serina Therapeutics Inc(SER) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 21 at 4:00 PM ET (Korea 10/22 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.88 | Insider Own | 51.2% | Shs Outstand | 25.4M | Perf Week | 3.51% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 26.95% | Insider Trans | 0.34% | Shs Float | 12.4M | Perf Month | -23.38% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | -0.34 | Inst Own | 5.71% | Short Float | 0.46% | Perf Quarter | -15.31% |
| Income | -0.02B | P/S | - | EPS this Y | 17.35% | Inst Trans | -2.07% | Short Ratio | 0.88 | Perf Half Y | -9.23% |
| Sales | 0.00B | P/B | 2.4 | EPS next 5Y | 18.02% | ROA | -121.85% | Short Interest | 0.06M | Perf YTD | -7.48% |
| Book/sh | 0.74 | P/C | 1.95 | EPS past 3/5Y | 41.84% 28.41% | ROE | -206.26% | 52W High | -66.54% ($5.29) | Perf Year | -63.88% |
| Cash/sh | 0.91 | P/FCF | - | Sales past 3/5Y | - 19.21% | ROIC | -96.52% | 52W Low | 45.08% ($1.22) | Perf 3Y | -92.26% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 67.71% | Gross Margin | - | Volatility(W/M) | 8.69% 7.01% | Perf 5Y | -94.44% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.15 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.65 | EPS Q/Q | 15.42% | Profit Margin | - | RSI (14) | 38.13 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.65 | Sales Q/Q | -100% | SMA20 | -7.79% ($1.92) | Beta | 1.3 | Target Price | $9.5 |
| Payout | - | Debt/Eq | 0.17 | Earnings | 2026/8/13 | SMA50 | -22.71% ($2.29) | Rel Volume | 0.62 | Prev Close | $1.66 |
| Employees | 16 | LT Debt/Eq | 0.17 | EPS/Sales Surpr. | -17.95% - | SMA200 | -16.31% ($2.11) | Avg Volume(3M) | 0.06M | Price | $1.77 |
| IPO | 2018/11/29 | Option/Short | No/Yes | Trades | 61 | Volume | 39,747 | Change | 6.63% |
🧠 Serina Therapeutics () is a clinical-stage biotech headquartered in Huntsville, Alabama, USA, developing treatments for neurological disorders based on its proprietary "POZ (polyoxazoline)" drug delivery platform. Its lead pipeline candidate is long-acting apomorphine <b>SER-252 (POZ-apomorphine)</b> for patients with advanced Parkinson's disease, which has entered registrational clinical trials via the FDA's 505(b)(2) pathway.
Over the past 1 year, on the lower side
67% below its 1-year high.
Traded less than usual. That is 62% of its average volume.
SER has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +17.4% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.4%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% 
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
XLC State Street Communication Services Select Sector SPDR ETF 23.4B 
IGM iShares Expanded Tech Sector ETF 10.9B 
VOX Vanguard Communication Services ETF 5.8B 
NFRA Northern Trust STOXX Global Broad Infrastructure ETF 3.0B 
OIH VanEck Oil Services ETF 1.8B It ranks #426 of 595 in the industry
Based on market cap of $45M.
ATHE#424 Alterity Therapeutics Ltd ADR $46M PER - 
ELTX#425 Elicio Therapeutics Inc $45M PER - SER#426 Serina Therapeutics Inc $45M PER - 
INMB#427 INmune Bio Inc $45M PER - 
KLRS#428 Kalaris Therapeutics Inc $44M PER - 
FAQ
What kind of company is SER?
SER belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SER?
The market cap of SER is approximately $45M, ranking 4,906 within its sector.
What is the 52-week high and low for SER?
SER has recorded a 52-week high of $5.29 and a low of $1.22.
